Chemoimmunotherapy in Early TNBC: Higher pCR, Fragile Survival Signal, Added Toxicity
This updated meta-analysis of eight randomized trials adds adjuvant data and Asian-population evidence to the neoadjuvant picture, and gives oncology pharmacists a pooled view of efficacy against the toxicity burden of adding PD-1 or PD-L1 blockade to chemotherapy in non-metastatic triple-negative breast cancer.
📅 Journal publication: 2026(online Jun 24, 2026)·Last updated: Nov 18, 2026
ICIs and chemotherapy boost outcomes in early-stage TNBC.
This study evaluates the effectiveness and safety of combining chemotherapy with immune checkpoint inhibitors (ICIs) for non-metastatic triple-negative breast cancer (TNBC), informing treatment strategies. Combined therapy improves pathological complete response (pCR) rates (OR = 1.82) and event-free survival (EFS) (HR = 0.73), but increases serious adverse events (SAEs) (RR = 1.70). The findings suggest improved outcomes with ICI-based regimens in early-stage TNBC, though with a notable increase in adverse events. ICIs with chemotherapy improve outcomes in non-metastatic TNBC but increase serious adverse events.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Wu J, Zhang K
Citation:Wu J, Zhang K Benefits and adverse events of combined chemotherapy and immune checkpoint inhibition in non-metastatic triple-negative breast cancer: a systematic review and an updated meta-analysis. Translational breast cancer research : a journal focusing on translational research in breast cancer. 2026;7:46. doi:10.21037/tbcr-2026-0031